

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rosenblum et al. § ART UNIT: 1642

FILED: January 7, 1999

EXAMINER:

K. Canella SERIAL NO.: 09/226,895

FOR: Potentiation of Anti-CD38-

Immunotoxin Cytotoxicity DOCKET: D6205

The Assistant Commissioner of Patents and Trademarks

RECEIVED

BOX NON-FEE AMENDMENT

MAR 0 8 2001 Washington, DC 20231

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Commissioner of Patents and Trademarks, Washington DC 20231.

- 1) Response to Office Action (6 Pages);
- 2) Return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

(713) 270-5391

badler1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

Counsel for Applicant

Registration No. 35,423

BADEN IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rosenblum et al. § ART UNIT: 1642

FILED: January 7, 1999 §

§ EXAMINER:

FOR: Potentiation of Anti-CD38-

Immunotoxin Cytotoxicity § DOCKET: D6205

The Assistant Commissioner of Patents and Trademarks BOX NON-FEE AMENDMENT

BOX NON-FEE AMENDMENT
Washington, DC 20231

RECEIVED

MAR 0 8 2001

TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed December 7, 2000, please enter the following remarks. Reconsideration of the pending claims in view of these remarks is respectfully requested.

REMARKS

The 35 U.S.C. §103 Rejections

Claims 1, 7-9 and 11 stand rejected under 35 U.S.C. §103(a) as unpatentable over **Mehta** et al. (Proceeding of the American Association for Cancer Research, 38:88, 1997) in view of